The neurometabolic disorder glutaric aciduria type 1 (GA1) is caused by mutations in the GCDH gene encoding the mitochondrial matrix protein glutaryl-CoA dehydrogenase (GCDH), which forms homo-and heteromeric complexes. Twenty percent of all pathogenic mutations affect single amino acid residues on the surface of GCDH resulting in a severe clinical phenotype. We report here on heterologous expression studies of 18 missense mutations identified in GA1 patients affecting surface amino acids. Western blot and pulse chase experiments revealed that the stability of half of the GCDH mutants was significantly reduced. In silico analyses showed that none of the mutations impaired the 3D structure of GCDH. Immunofluorescence co-localisation studies in HeLa cells demonstrated that all GCDH mutants were correctly translocated into mitochondria. Surprisingly, the expression of p.Arg88Cys GCDH as well as further substitutions by alanine, lysine, or methionine but not histidine or leucine resulted in the disruption of mitochondrial architecture forming longitudinal structures composed of stacks of cristae and partial loss of the outer mitochondrial membrane. The expression of mitochondrial fusion or fission proteins was not affected in these cells. Bioluminescence resonance energy transfer analyses revealed that all GCDH mutants exhibit an increased binding affinity to electron transfer flavoprotein beta, whereas only p.Tyr155His GCDH showed a reduced interaction with dihydrolipoamide succinyl transferase. Our data underscore the impact of GCDH protein interactions mediated by amino acid residues on the surface of GCDH required for proper enzymatic activity. †
Introduction
The autosomal-recessively inherited neurometabolic disorder glutaric aciduria type 1 (GA1, OMIM 231670) is caused by mutations in the gene encoding the mitochondrial matrix enzyme glutaryl-CoA dehydrogenase (GCDH, E.C. 1.3.8.6 ., formerly designated as E.C. 1.3.99.7). GCDH is a member of the acyl-CoA dehydrogenase family of mitochondrial flavoproteins, and catalyses the oxidative decarboxylation of glutaryl-CoA in the degradation pathway of the amino acids lysine, hydroxylysine, and tryptophan (1) (2) (3) . Deficiency of GCDH leads to accumulation of the pathologic dicarboxylic acids glutaric acid (GA) and 3-hydroxyglutaric acid (3OHGA) in tissues and body fluids. GA1 patients are at risk to develop encephalopathic crises promoted by catabolic conditions such as infections, fever, diarrhoea or vomiting. These crises are accompanied by a further increase of GA and 3OHGA concentrations, and a selective irreversible destruction of striatal neurons with subsequent development of a dystonic/dyskinetic movement disorder of variable degree (1, 4) . Newborn screening programs allow for presymptomatic identification of GA1 patients, followed by initiation of an adequate therapy to avoid the development of encephalopathic crises (5) (6) (7) (8) .
GCDH is synthesised as a 438 amino acid precursor protein, of which a 44 N-terminal amino acid mitochondrial targeting signal is cleaved off after import into mitochondria (9) . The oligomerisation of four GCDH monomers containing a noncovalently bound flavin adenine dinucleotide (FAD) results in the enzymatically active GCDH tetramer (10) .
More than 150 different disease-causing GCDH mutations with predominance in specific populations have been described, which lead to a wide spectrum of clinical symptoms in GA1 patients ranging from an asymptomatic to a severe disabling course of the disease (11) . The genotype thereby correlates with residual GCDH activity and with the extent of GA and 3OHGA excretion (9, 12, 13) , whereas no correlation exists between the genotype and the clinical course of the disease (14) . All mutations analysed so far affecting the catalytic centre of GCDH lead to a complete loss of enzymatic activity, whereas most patients displaying residual GCDH activities ranging between 5 and 30% of healthy controls are homozygous or compound heterozygous for mutations that affect amino acid residues localised on the surface of the GCDH protein (9, 12, (15) (16) (17) (18) (19) (20) .
In addition to homotetramerisation, we have shown recently that GCDH is capable to form heteromeric protein complexes, e.g. with the electron transfer flavoprotein subunit b (ETFB) and dihydrolipoamide S-succinyltransferase (DLST; 20, 21), suggesting that GCDH might be part of multienzyme complexes.
In the present study, we selected 18 disease-causing GCDH mutations affecting amino acid residues localised on the surface of the GCDH protein, and analysed their effect on the stability and subcellular localisation of GCDH in HeLa cells. Furthermore, we determined the capability of mutant GCDH to interact with ETFB and DLST using bioluminescence resonance energy transfer (BRET).
Our data suggest that pathogenic GCDH mutations localised on the protein surface impair protein stability and interaction with other proteins rather than affecting subcellular localisation or direct catalytic activity. Our data underscore the hypothesis that GCDH function requires the formation of GCDH-containing multienzyme complexes.
Results

Selection of amino acid residues on the GCDH protein surface
For the study, initially 33 disease-causing missense mutations affecting amino acid residues on the protein surface were selected. Based on in silico analyses of the GCDH 3D model (2), 13 amino acid residues (p.Arg132Gln, p.Cys176Arg, p.Gly178Arg, p.Gln333Glu, p.Thr341Pro, p.Ala349Thr, p.Arg372Lys, p.Arg383Cys/His, p.Arg386Gly/Gln, p.Gly390Ala/Val/Arg, p.Ala421Thr/Val, p.Thr429Met and p.Ala433Glu/Val) known to be involved in GCDH homotetramerisation were excluded. Furthermore, p.Leu283Pro and p.Glu365Lys were excluded due to their localisation in close spatial proximity to the catalytic centre. The remaining surfacelocalised 18 amino acid residues and the corresponding diseasecausing mutations analysed here are shown as 1. allele in Table 1 , and Supplementary Material, Fig. S1 . Table 1 summarises the molecular, biochemical and clinical findings of patients carrying the 18 mutations to be studied.
Effects of pathogenic missense mutations on the GCDH protein 3D structure and surface potential
The physiologically active human GCDH protein exists as a tetramer in vivo and in crystallo (PDB-ID: 1siq/sir). Each monomer consists of an N-terminal helical bundle (helices A-F), a C-terminal helical bundle (helices G-K) and a connecting immunoglobulinlike b-sandwich (see (2) for definitions of secondary structure elements). The FAD ligand is located between the C-terminal bundle and the b-sandwich. In the tetramer, the ligand-binding site is located in between two adjacent monomers.
In order to analyse possible structural effects of diseaserelated mutations, the affected residues were first generated and visualized on the 3D surface representation of human GCDH (Supplementary Material, Fig. S1 ). They are located on the solvent exposed surface (i.e. not in the tetramer interface) of the GCDH monomer and do not cluster in a particular region. The mutations can be categorised into various groups: Several disease-related mutations contain substitutions where charged residues are replaced by hydrophobic residues (e.g. p.Arg88Cys, p.Arg94Leu, p.Arg227Pro, p.Arg355His). Others introduce new charges in positions that contain small, uncharged residues in the wild-type protein (e.g. p.Gly101Arg, p.Gly117Arg). The p.Glu90Lys mutation replaces a negatively charged residue with a positively charged residue. Another group of disease-related mutations are those that replace a small neutral residue with a larger one (e.g. p.Cys115Tyr, p.Ser119Leu, p.Pro217Leu, p.Gly244Cys) or a large residue by a smaller one (e.g. p.Trp50Cys, p.Met263Val).
Most investigated mutations affect surface exposed side chains. The mutated residues are not found in regular secondary structure elements but rather in connecting loops that are solvent exposed. Thus, it is very likely that the mutations do not cause a significant change in the three-dimensional structure of GCDH, but rather subtle local changes. Nevertheless, those changes on the surface of the protein may result in binding affinity changes to different binding partners via e.g. changes in surface electrostatics or changes in complementary surface geometry.
To investigate the effect of missense mutations on the surface potential of the GCDH protein, we mutated the 3D structure of human GCDH at the relevant positions by exchanging the residues followed by energy minimization. Four of 18 mutations showed no or only small (p.Tyr113His, p.Cys115Tyr, p.Ser119Leu, p.Gly244Cys) alterations of surface charge, whereas the remaining 14 mutations examined here lead to electrostatic changes on the surface (Fig. 1) . The most prominent effects can be observed for p.Glu90Lys, which introduces a positive surface patch at the interface between helix B and the b-sandwich domain. Other characteristic electrostatic effects include the p.Gly117Arg mutation, leading to a positively charged crevice between loop C-D and helix H, and the p.Arg355His mutation, which introduces a positive surface potential between the N-terminus of helix A and the C-terminal end of helix H. Interestingly, both the p.Gly117Arg and p.Arg355His mutations affect the same region on the GCDH protein, but introducing the opposite charge, indicating that the correct surface potential is an important parameter for the function of GCDH.
Pathogenic surface amino acid substitutions affect GCDH protein expression
The selected mutations were introduced into wild-type GCDHmyc cDNA by site-directed mutagenesis, inserted into a pcDNA6.2/V5/GW/TOPO expression vector, followed by coexpression with GFP in HeLa cells. Myc-specific western blots showed a variable degree of protein expression of the various GCDH mutants (Fig. 2A) . Quantification of the myc-specific signals and normalisation to immunoreactive GFP and b-tubulin as transfection and loading control, respectively, revealed that the steady state level of p.Gly101Arg-, p.Ser119Leu-, and p.Gly244Cys-GCDH was strongly reduced to 14.7 6 5.1, 15.8 6 9.3, and 12.8 6 8.3% of wild-type GCDH, respectively (Fig. 2B) . The relative expression of mutant p.Gly117Arg, p.Pro217Leu, p.Arg227Pro, p.Pro248Leu, p.Met263Val and p.Arg355His GCDH varied between 31 and 53% of wild-type (Fig. 2B) , whereas p.Trp50Cys, p.Arg88Cys, p.Glu90Lys, p.Arg94Leu, p.Tyr113His, p.Cys115Tyr, p.Tyr155His, p.Arg161Gln and p.Pro278Ser GCDH showed levels comparable to wild-type.
Mitochondrial localisation of GCDH is not affected by surface missense mutations
To examine whether the disease-related mutations affect the sorting and localisation of GCDH into mitochondria, double-immunofluorescence stainings were performed. HeLa cells were transfected with wild-type or mutant GCDH-myc, and stained for myc and the mitochondrial matrix marker protein manganese-dependent superoxide dismutase (MnSOD). Both wild-type and all mutant GCDHmyc constructs completely co-localised with MnSOD ( Fig. 3) , indicating their correct targeting and import into mitochondria.
p.Arg88Cys GCDH affects mitochondrial architecture
When the GCDH p.Arg88Cys mutant was expressed, the mitochondrial staining pattern was significantly changed resulting in GCDH/MnSOD immuno-positive tubular structures (Fig. 3B ).
To differentiate whether the tubular formation is caused by the exchange of Arg88 by Cys or by the position affected by the mutation, Arg88 or the neighbouring residues Asn87 and Asn89 were substituted by Ala followed by expression analyses. None 
S2B). GCDH mutants that harbour
His or Leu at residue 88 showed a similar localisation pattern as wild-type GDDH. In addition, substitution of the neighbouring residues Asn87 or Asn89 by Ala did not impair mitochondrial morphology. These experiments indicated that Arg88 of GCDH is important to maintain mitochondrial architecture and capability to fuse.
Transmission electron microscopy was used to identify and determine the appearance of mitochondria in HeLa cells transfected with wild-type and mutant GCDH (Fig. 4) . HeLa cells expressing p.Arg88Cys mutant showed a severely altered mitochondrial ultrastructure. An elongation and reorganization of mitochondrial membranes was found, and inner membrane alignment with several layers of tightly packed membranous sheets was observed (Fig. 4B ,D,F). These abnormal longitudinally arranged inner membranes filled the majority of the internal mitochondrial compartment. The outer mitochondrial membrane was partially destroyed (Fig. 4F ). Mitochondria were partially surrounded by endoplasmic reticulum (ER) membranes attached to tubular structures. Occasionally, empty mitochondrial structures lacking almost all cristae were observed (Supplementary Material, Fig. S3 ).
To examine whether p.Arg88Cys induced changes in mitochondrial architecture involve the actin cytoskeleton, cells were incubated with phalloidin in the presence or absence of 5 mM latrunculin. Double-immunofluorescence microscopy showed that neither wild-type nor p.Arg88Cys GCDH co-localised with phalloidin independent of the presence of latrunculin (Supplementary Material, Fig. S4 ). Neither the mRNA nor protein expression of mitochondrial fission protein 1 (Fis1), and mitochondrial fusion proteins mitofusin 1 and 2 (Mfn1, Mfn2) differed between wild-type-and p.Arg88Cys expressing HeLa cells, suggesting that neither mitochondrial fission nor fusion processes were affected by this mutant (Supplementary Material, Fig. S5 ).
Surface-located mutations affect GCDH protein stability
To examine whether the selected GCDH mutations lead to a decreased stability and an accelerated degradation of the mutant protein, pulse-chase experiments were performed. Thus, HeLa cells expressing wild-type or mutant GCDH were labelled with [
35 S]-methionine and either harvested immediately or chased for 24 h in the presence of unlabelled methionine. Subsequently, GCDH-Myc was immunoprecipitated from cell extracts and analysed by SDS-PAGE and fluorography. After 24 h, densitometric scanning analyses revealed that 40 to 54% of the initial wild-type GCDH-specific signal intensity could be observed ( Fig. 5 ), which is in line with previous observations (20) . The newly synthesised mutants p.Trp50Cys, p.Arg88Cys, and p.Glu90Lys GCDH showed a decrease of the GCDH-specific fluorography signal after 24 h chase period to 62, 88, and 36%, respectively, of the corresponding initial signal (no chase), which resembles the degradation rate of wild-type GCDH (Fig. 5 ). All other mutants examined revealed a moderate (p.Tyr113His, p.Tyr155His, p.Arg227Pro, p.Pro248Leu, p.Pro278Ser, and p.Arg355His) or even strong (p.Arg94Leu, p.Gly101Arg, p.Cys115Tyr, p.Gly117Arg, p.Ser119Leu, p.Arg161Gln, p.Pro217Leu, p.Gly244Cys, and p.Met263Val) increase in degradation, referring to a reduction of the GCDHspecific signal after 24 h chase to 10-26% (moderate) or 0-7% (strong), respectively, as compared to the corresponding initial [ 35 S]-GCDH signal directly after labelling (Fig. 5) . Arg94 is involved in interactions connecting helices C and F. Cys115, Gly117 and Ser119 are all located in a long loop connecting helices C and D. Changes in these structural features by introduction of larger side chains may result in increased degradation.
GCDH protein surface mutations affect GCDH homooligomerisation and the interaction of GCDH with ETFB or DLST
In order to analyse whether GCDH surface mutations have an effect on homo-and/or heterooligomerisation, we performed bioluminescence resonance energy transfer (BRET) experiments. For this purpose, human wild-type and mutant GCDH cDNAs, as well as ETFB and DLST cDNAs were fused at their carboxyl terminus to the energy donor Renilla reniformis luciferase (Rluc) and to the energy acceptor yellow fluorescent protein (YFP). Expression and mitochondrial localisation of the different fusion proteins was verified using western blot analyses and immunofluorescence microscopy. These experiments revealed a proper expression level for all fusion proteins (Supplementary Material, Fig. S6A ). Double immunofluorescence stainings of Rluc/YFP and the mitochondrial marker ATPB revealed a mitochondrial localisation for Rluc-DLST, YFP-ETFB, Rluc-GCDH and YFP-GCDH. No and partial co-staining with ATPB was observed for YFP-DLST and Rluc-ETFB, respectively (Supplementary n ¼ 5). Levels of significance were determined by one-way analysis of variance followed by Dunnetts Multiple Comparison Test. *P < 0.05, **P < 0.01, ***P < 0.001.
Material, Fig. S6B ). Therefore, we used the Rluc-GCDH/YFP-GCDH, Rluc-DLST/YFP-GCDH and Rluc-GCDH/YFP-ETFB pairs in the subsequent BRET assays.
Human GCDH functions as a tetramer (2), therefore we analysed whether the different surface mutations indirectly impair the formation of GCDH homooligomers. HEK293T cells were cotransfected with increasing GCDH-YFP to GCDH-Rluc ratios of wild-type and the various mutant GCDH forms, respectively. BRET saturation experiments allow for determination of relative binding affinities (BRET 50 ), given as the inverse acceptor to donor ratio at half-maximal BRET ratios. Most GCDH mutants had no negative impact on oligomer formation. In fact, mutations p.Gly101Arg, p.Cys115Tyr, p.Ser119Leu, p.Tyr155His, p.Arg161Gln, p.Arg227Pro, p.Met263Val and p.Arg355His even showed a significant increase in the binding affinity of about two fold (e.g. p.Met263Val with BRET 50 positive interaction (Supplementary Material, Fig. S8 ), indicating that these amino acid substitutions affect the stability of the homomeric complex. BRET max is a function of distance and spatial orientation of Rluc and YFP fused to the C-terminus of GCDH. Conformational changes of the GCDH complex, indicated by significantly decreased BRET max values, were observed for all GCDH mutants except p.Arg88Cys, p.Glu90Lys, p.Tyr155His, p.Pro248Leu, p.Met263Val and p.Pro278Ser (Table 2B , Supplementary Material, Fig. S7 ).
In addition to homooligomerisation GCDH forms heteromeric protein complexes with DLST and ETFB (21) . Both DLST as well as ETFB are known to be components of several mitochondrial dehydrogenase multienzyme complexes involved in the formation of the glutaryl-CoA substrate of GCDH and in electron transfer, respectively. This indicates that GCDH does not act as a homomeric enzyme alone but may rather be part of a multienzyme complex. Thus, we further analysed whether mutations of GCDH surface amino acid residues may mediate their disease-causing effects not primarily by a reduced GCDH activity but rather via negative effects to the binding of GCDH to its heteromeric interaction partners, thus interfering with the function of the whole multienzyme complex. For BRET saturation assays HEK293T cells were co-transfected with increasing YFP-GCDH to Rluc-DLST ratios and with increasing YFP-ETFB to Rluc-GCDH ratios, respectively. Based on BRET 50 , the binding affinity to ETFB was significantly increased for all tested GCDH mutants up to 6 fold (e.g. p.Gly101Arg with BRET 50 1.40) in comparison to wild-type GCDH (BRET 50 8.61) (Table 2A , Supplementary Material, Fig. S9 ). Nevertheless, for the mutations p.Gly117Arg, p.Ser119Leu and p.Pro217Leu only 86, 88, and 75% could be classified as positive interaction (Supplementary Material, Fig. S10 ), indicating that these amino acid substitutions affect the complex formation with ETFB. Despite the changes in binding affinity, no significant conformational alterations could be observed as determined by BRET max (Table 2B , Supplementary Material, Fig. S9) .
In contrast to ETFB the interaction of GCDH with DLST appears to be largely mediated by a single amino acid residue, p.Tyr155. Tyr155 is located at the C-terminal end of helix E at the interface to helix G. The substitution of the tyrosine to histidine led to a twofold decrease of the binding affinity in comparison to wild-type GCDH (Table 2A , Supplementary Material, Fig. S11 ), and only 71% of the tested interactions could be classified as positive. In addition, the p.Gly101Arg-, p.Tyr113His-, p.Pro217Leu-, p.Arg227Pro-, and p.Arg355His-GCDH mutants showed a decreased rate of positive interactions of 40, 83, 75, 75, and 83%, respectively, of all interactions tested, indicating a negative impact of these mutations on the complex formation with DLST (Supplementary Material, Fig. S12 ). Like for ETFB no significant conformational changes could be observed as determined by BRET max (Table 2B , Supplementary Material, Fig. S11 ).
Discussion
Homotetrameric GCDH directly interacts with other mitochondrial matrix proteins such as dihydrolipoamide S-succinyltransferase (DLST) and the FAD-containing heterodimer electron transfer flavoprotein (ETF; 21). DLST constitutes a subunit of the large 2-oxoglutarate dehydrogenase complex (OGCD) that catalyses the rate-limiting step of oxidative decarboxylation of both a-ketoglutarate and a-ketoadipate to succinyl-and glutarylCoA, respectively, in the tricarboxylic acid cycle (22, 23) . The consecutive catalytic reaction of DLST and GCDH within a multienzyme complex appears to be a prerequisite for an efficient oxidative decarboxylation of glutaryl-CoA to crotonyl-CoA and maintenance of amino acid homeostasis. There is growing evidence that various individual protein complexes assemble into supercomplexes, which are essential for stability and substrate channelling and play an important role in diseases (24) . ETF on the other hand serves as electron acceptor for nine mitochondrial dehydrogenases which are involved in fatty acid oxidation and amino acid catabolism (25) .
In this context, it is likely that pathogenic mutations affecting amino acid residues localised on the surface of the GCDH protein, which are mostly associated with high residual GCDH activities in vitro but result in a severe course of GA1 disease, cause defects in GCDH heteromeric complex formation. We selected 18 mutations affecting amino acid residues on the GCDH protein surface and found that 8 mutations (p.Gly101Arg, p.Gly117Arg, p.Ser119Leu, p.Arg227Pro, p.Gly244Cys, p.Pro248Leu, p.Met263Val, and p.Arg355His) led to a reduction of steady-state GCDH protein expression by ! 60% compared with wild-type GCDH. Furthermore, pulse-chase experiments demonstrated that with the exception of 2 mutations (p.Trp50Cys and p.Arg88Cys) all other mutations strongly decreased the half-life of GCDH ($24h, Fig. 5; 20 ). It appears that these mutations prevent proper refolding after translocation into the The p.Arg88Cys-GCDH mutant, however, is of special interest because its overexpression altered mitochondrial morphology and ultrastructure into long tube-like profiles composed of stacks of cristae ( Figs 3 and 4, Supplementary Material, Fig.  S3 ). A number of these mitochondria showed ruptured outer membranes with blebs partially resembling alterations in mitochondrial morphology in response to apoptotic Fas activation in mouse liver (26) . Previously, we have described changes in size and electron density of mitochondria in proximal tubular cells diff. ¼ difference; SE ¼ standard error of the mean; p.i. ¼ positive interaction; ns ¼ not significant; *P 0.05; **P 0.01; ***P 0.001 as compared to wild-type.
Relative binding affinity (BRET50, A), and maximal BRET ratio (BRETmax, B) of the three different interaction studies (oligomerisation of mutant GCDH, mutant GCDH þ ETFB and mutant GCDH þ DLST) determined by nonlinear regression analyses assuming a one-site binding site (GraphPad Prism). BRET 50 and BRET max values expressed as mean of 4-12 independent experiments per interaction study. Differences between mutant and wild-type GCDH are indicated 6 SE. Statistical significance was determined using one-way ANOVA followed by Dunnetts multiple comparison test.
of Gcdh-deficient mice under induced metabolic crises (27) . It might be interesting to analyse fibroblasts or cultured proximal tubule cells from homozygous p.Arg88Cys GA1 patients (28) to see whether the mutation also affects the endogenous morphology of mitochondria. Substitution of Arg88 with His or Leu did not impair mitochondrial architecture, whereas substitution by Ala, Lys or Met led to a similar disruption of mitochondrial structure as the p.Arg88Cys mutant. However, replacement of neighbouring Asn87 or Asn89 by Ala residues failed to affect the mitochondrial profile ( Supplementary  Material, Fig. S2 ). These data suggest that specifically arginine is required at position 88, which is involved in electrostatic interactions with Asp396 and Glu397 thus connecting the N-and Cterminal helical bundles via helices B and J (2). It is tempting to speculate that this structural feature is important for maintaining the mitochondrial architecture and most likely for a still unknown protein-protein interaction which is independent on surface charge. The identification of this potential GCDH partner which could be part of the mitochondrial contact site and cristae organisation system (MICOS) complex (29) and the role of GCDH in disassembly of mitochondrial cristae remain to be solved.
In silico analyses revealed that in the majority of the 18 selected mutants the amino acid substitution goes along with a localised alteration of the surface potential, of which p.Glu90Lys, p.Gly117Arg, and p.Arg355His showed the most striking changes. Surface charge-charge relationships are known to be important to drive protein-protein interactions (30) , and are crucial for protein stability (31) .
To test for specific effects of GCDH mutations on homo-and heteromeric protein interactions, BRET analyses were performed. The most surprising observation was that all tested mutants showed a significant increase in the binding affinity between GCDH and ETFB (reduced BRET 50 values) compared to wild-type GCDH. It has previously been described that not only de-but also increased affinities of protein-protein interactions detected by BRET analyses indicate functional disturbances of this interaction (32, 33) . It is likely that the increased affinity reduces the dissociation rate of ETFB from mutant GCDH, which might impair the electron flux and GCDH activity. A precisely regulated equilibrium between the association and dissociation might be especially important for components in a multienzyme complex such as GCDH and OGCD (34) (35) (36) . The reduced rate of positive interactions between GCDH mutants p.Gly117Arg, p.Ser119Leu and p.Pro217Leu with ETFB indicates that these amino acid substitutions may affect the complex formation with ETFB. These mutations have in common that they all contain "small-to-large" side chain substitutions. It has been reported previously that the mitochondrial medium-chain acylCoA dehydrogenase (MCAD), which shows an overall sequence homology of 28% to GCDH, interacts with ETFB via nine residues in the N-terminal domain of MCAD, Glu22, Phe 23, Thr26, Glu34, Gly60, Thr64, Leu73, Leu75 and Ile83 (37) . Due to low homology in this domain only 2 of 9 identical amino acids exist between MCAD and GCDH (Thr26 and Gly60 of MCAD), which does not allow any conclusions on similarities between the ETFB-binding region in MCAD and GCDH. Although we have excluded missense mutations from this study known to be directly involved in GCDH homooligomerisation, several GCDH mutants appeared to stabilise mutant homooligomeric GCDH complexes. Finally, only the p.Tyr155His-GCDH mutant showed an elevated BRET 50 value for the interaction with DLST, indicating a reduced affinity and a direct involvement of Tyr155 in the binding to DLST. In addition, a decreased rate of positive GCDH-DLST interactions of the p.Gly101Arg-, p.Tyr113His-, p.Pro217Leu-, p.Arg227Pro-, and p.Arg355His mutants indicates a negative impact of these mutations on the complex formation with DLST. While there is no obvious pattern with respect to type of amino acid substitution in these mutants, most of the affected residues cluster around a potential binding crevice formed by helices D, E, G, H and the connecting loop C-D. Thus, it is tempting to speculate that these structural elements are involved in binding to DLST.
Taken together, we showed that mutations of amino acid residues that are localised on the GCDH protein surface lead to decreased protein stability and alterations of the electrostatic properties impairing homo-and heteromeric GCDH interactions. In addition, we identified Arg88 to be essential for preserving mitochondrial architecture and GCDH activity ( Table 1) . Further investigations are needed to elucidate the role of GCDH and in particular Arg88 in the mitochondrial contact site and cristae organisation system (MICOS).
Materials and Methods
Reagents
The following reagents were obtained commercially as indi 
DNA constructs
The human GCDH-Myc in the pcDNA6.2/V5/GW/TOPO vector has been described previously (20 Table S1 .
Cell culture and transfection
HeLa cells were cultured in DMEM supplemented with 10% FCS and penicillin/streptomycin in a humidified atmosphere containing 5% CO 2 at 37 C. Cells grown on 6-cm plates were transfected with the indicated cDNAs using jetPEI TM transfection reagent according to the manufacturer's instructions. The cells were used 24 h after transfection.
Cell fractionation and western blotting
At 24 h after transfection cells were lysed in 10 mM phosphatebuffered saline pH 7.4 (PBS) containing 0.2% Triton X-100 and protease inhibitors for 10 min at 4 C. After centrifugation at 10,000 Â g, supernatants were used for measurement of the protein content by the Roti V R quant Protein Assay. Aliquots of cell extracts (100 lg protein) were solubilized, separated by SDS-PAGE (10% acrylamide) and analysed by Western blotting, using antiMyc (1:1000), anti-GFP (1:1000) and anti-b-Tubulin (1:1000). After incubation with secondary HRP-conjugated goat anti mouse or goat anti rabbit IgG antibody, the immunoreactive bands were visualized by enhanced chemiluminescence. In silico modelling of effects of GCDH mutations on the 3D protein structure
Immunofluorescence microscopy
Models of the GCDH mutants were obtained by exchanging the residues at the respective positions, according to the sequence numbering of the full-length GCDH precursor molecule. The Xray crystal structure of GCDH was retrieved from the RCSB Protein Data Bank (PDB entry code: 1siq/sir). The electrostatic surface potential models were generated by SYBYL (TRIPOS, INC). Figures were generated using PYMOL (The PYMOL Molecular Graphics System 2002, DeLano Scientific, San Carlos, USA).
Metabolic labelling and immunoprecipitation
At 24 h after transfection, cells were metabolically labelled with [
35 S]-methionine (150 mCi/ml) in methionine-free DMEM for 45 min. After removing the labelling medium, cells were washed twice with PBS and either harvested or chased in DMEM containing 0.1% bovine serum albumin (BSA) and 0.25 mg/ml methionine for 24h. Cells were lysed in lysis buffer (0.4% Triton X-100, 0.2% sodium deoxycholate, 0.2% sodium dodecylsulfate, 1% BSA in PBS). After successive removal of DNA with 50 U benzonase and 0.03% protamine sulphate, extracts were preabsorbed with mouse IgG and protein A agarose for 60 min at 4 C.
After precipitation of the agarose beads (500 Â g for 20 min at 4 C), supernatants were mixed with mouse anti-Myc antibody
(1:500) and incubated for 12 h at 4 C. The immunocomplexes were precipitated with protein A agarose, washed, and processed for SDS-PAGE under reducing conditions (10% acrylamide), followed by fluorography.
Real-time PCR
Total RNA isolation, cDNA synthesis and real-time PCR were performed as previously described (40) . The relative expression of Fis1, Mfn1 and Mfn2 mRNA was normalized to the level of ACTB mRNA in the same cDNA using the comparative CT method (2 -DDCT ).
Bioluminescence resonance energy transfer (BRET)
Interactions between wild-type/mutant GCDH and DLST or ETFB were tested using bioluminescence resonance energy transfer (BRET), where Rluc served as donor and YFP served as the acceptor of energy transfer, occurring when proteins physically interact (41) . BRET saturation experiments were performed to distinguish a true positive interaction from bystander BRET resulting from random collision, and to analyse relative binding affinity. Therefore HEK293T cells (250,000 cells per 96 well plate) were co-transfected with increasing acceptor-to-donor ratios with a total of 2 lg DNA. After 24 h incubation at 37 C, coelenterazine (30 lM) was added to the living cells, and light emission was collected in a 96-well microplate luminometer LUMIstar OPTIMA (PHERAstar FS, BMG Labtech) for 10 s at 475 nm (Rluc signal) and 535 nm (BRET signal). The BRET ratio was calculated based on R ¼ IA/ID À cf, where R is the BRET ratio, IA is the intensity of light emission at 535 nm, ID is the intensity of light emission at 475 nm, and cf is a correction factor (BRETcontrol/ Rluccontrol) with the control being the cotransfection of donor fusion-proteins with YFP in the absence of a second protein of interest. In addition, the background of a noDNA control was subtracted, general BRET efficiency was tested by a YFP-Rluc fusion protein, and assay performance was evaluated using a standard protein interaction pair (b-Jun and b-Fos; (42) ). The saturation experiments were analysed using the Akaike's method (GraphPad Prism) to distinguish non-linear regression (true positive interaction) and linear regression (false positive interaction). For the non-linear regression model, parameters were subsequently calculated by Y ¼ BRET max x (X/BRET 50 þ X), where BRET max is the maximal BRET ratio describing the distance between donor and acceptor, and BRET 50 is the acceptor-to-donor ratio required to reach half-maximal BRET reflecting the relative binding affinity between donor and acceptor (43) . An interaction was assumed to be true positive if the preferred model was non-linear, with an R 2 > 0.8 and if the maximum BRET ratio exceeded the threshold of 0.02 for positive interactions.
Electron microscopy
Cultured HeLa cells were harvested and fixed with a mixture of 4% paraformaldehyde and 1% glutaraldehyde in PB pH 7.2. Thereafter they were spun down and washed several times in PBS. The pellets were first embedded in 2.5% agarose and dehydrated in an ascending series of ethanol. They were further transferred into a 1:1 mixture of Epon and propylene oxide and finally embedded and polymerized in neat Epon at 60 C for 48
h. Semithin sections (0.5 mm) were prepared for light microscopy, mounted on glass slides and stained for 1 min with 1% Toluidine blue. Ultrathin sections (60 nm) were cut and mounted on copper grids. Sections were stained using uranyl acetate and lead citrate. Thin sections were examined and photographed using an EM902 (Zeiss) electron microscope equipped with a TRS 2K digital camera (A. Trö ndle, Moorenweis, Germany).
Data analyses
Significance was determined by one-way Anova followed by Dunnetts Multiple Comparison Test using GraphPad Prism software. In all tests differences were considered significant at P < 0.05.
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